Journal
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
Volume 139, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.biocel.2021.106057
Keywords
AXL; RTK signaling; Targeted therapy; Combination therapies; TNBC
Categories
Funding
- Israel Science Foundation (ISF) [1530/17]
- Helen and Martin Kimmel Stem Cell Research Institute
Ask authors/readers for more resources
AXL, a tyrosine kinase receptor in the TAM family, is a promising therapeutic target for various hematological cancers and solid tumors. It plays a role in multiple protumorigenic processes and targeting AXL alone or in combination with other therapeutic agents could be beneficial, particularly in triple negative breast cancer.
The tyrosine kinase receptor AXL of the TAM (TYRO3, AXL and MERTK) family is considered as a promising therapeutic target for different hematological cancers and solid tumors. AXL is involved in multiple protumorigenic processes including cell migration, invasion, epithelial-mesenchymal transition (EMT), and stemness, and recent studies demonstrated its impact on cancer metastasis and drug resistance. Extensive studies on AXL have highlighted its unique characteristics and physiological functions and suggest that targeting of AXL could be beneficial in combination with chemotherapy, radiotherapy, immunotherapy, and targeted therapy. In this mini review, we discuss possible outcomes of AXL targeting either alone or together with other therapeutic agents and emphasize its impact on triple negative breast cancer (TNBC).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available